Amy Beth Vanduyn Sells 1,311 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 1,311 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $34,885.71. Following the completion of the sale, the senior vice president now directly owns 115,633 shares of the company’s stock, valued at $3,076,994.13. This trade represents a 1.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The shares were sold at an average price of $20.93, for a total transaction of $532,605.71.

Phreesia Price Performance

Shares of Phreesia stock opened at $28.42 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $22.70 and a 200-day simple moving average of $22.57. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -19.33 and a beta of 0.94. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.16.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business’s revenue was up 16.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.58) EPS. On average, sell-side analysts expect that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PHR shares. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Tuesday, December 10th. JMP Securities restated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird cut their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $24.00 to $32.00 in a research note on Wednesday. Finally, Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia presently has an average rating of “Buy” and a consensus price target of $30.64.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. International Assets Investment Management LLC lifted its holdings in shares of Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after buying an additional 1,395 shares during the last quarter. Lombard Odier Asset Management USA Corp bought a new position in Phreesia during the second quarter worth $202,000. Point72 DIFC Ltd bought a new position in Phreesia during the second quarter worth $209,000. XTX Topco Ltd acquired a new position in Phreesia during the 3rd quarter valued at $247,000. Finally, Hsbc Holdings PLC bought a new stake in Phreesia in the 2nd quarter valued at $301,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.